P. Rutgeerts

Publications1,677
h-index148
Citations107,053
Highly Influential Citations2,992
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • W. Sandborn
  • 2,038 Publications • 111,543 Citations
  • S. Vermeire
  • 1,676 Publications • 76,801 Citations
  • J. Colombel
  • 1,813 Publications • 101,552 Citations
  • B. Feagan
  • 1,068 Publications • 59,982 Citations
  • Publications
  • Influence
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
TLDR
The results strongly confirm 11 previously reported loci and provide genome-wide significant evidence for 21 additional loci, including the regions containing STAT3, JAK2, ICOSLG, CDKAL1 and ITLN1, which offer promise for informed therapeutic development. Expand
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
TLDR
A meta-analysis of six Crohn's disease genome-wide association studies and a series of in silico analyses highlighted particular genes within these loci implicated functionally interesting candidate genes including SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP. Expand
Infliximab, azathioprine, or combination therapy for Crohn's disease.
TLDR
Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy. Expand
Infliximab for induction and maintenance therapy for ulcerative colitis.
TLDR
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. Expand
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
TLDR
The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment, and concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response. Expand
Infliximab maintenance therapy for fistulizing Crohn's disease.
TLDR
Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks. Expand
Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test.
TLDR
The octanoic acid breath test is a reliable noninvasive test to measure gastric emptying rate of solids and would be applicable to field testing. Expand
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
TLDR
The aim of this study was to develop and to prospectively validate a simpler endoscopic score of disease activity, the Simple Endoscopic Score for Crohn's Disease, which was correlated to clinical parameters and serum C-reactive protein level. Expand
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
TLDR
Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks. Expand
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
TLDR
Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups. Expand
...
1
2
3
4
5
...